Rotavirus VP7 G9 glycoprotein (VP7 G9)

The Rotavirus VP7 G9 glycoprotein is a major structural component of the outer capsid of the rotavirus, specifically defining the G9 serotype (UniProt P04502). As a glycoprotein, it plays a critical role in the virus's ability to attach to and enter host intestinal cells, making it a primary target for the host's immune system (PubMed: 25135127). The G9 serotype has emerged globally as a significant cause of severe gastroenteritis in infants and young children, often leading to dehydration and hospitalization (WHO, 2021). Because VP7 is highly immunogenic, it serves as a key antigen in the development of rotavirus vaccines. Vaccines like Rotavac and Rotasiil specifically incorporate or target the G9 serotype to provide protection against this prevalent strain (PubMed: 30245168). Neutralizing antibodies directed against VP7 prevent the virus from infecting cells by stabilizing the trimer and inhibiting the uncoating trigger (PubMed: 21248043). Understanding the structural and genetic variations of the G9 glycoprotein is essential for monitoring vaccine efficacy and the emergence of new viral variants.

Other names

Outer capsid glycoprotein VP7G9 serotype VP7VP7 proteinG9 glycoproteinG9P[11] antigenG9P[5] antigen

Induction of neutralizing antibodies that stabilize the VP7 trimer and block viral uncoating and entry into host cells.